Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Sirona’s Technology Platform

- Sirona Biochem, through our wholly owned subsidiary, TFChem, has developed safer, more effective cosmetic and pharmaceutical active ingredients.

- Sirona Biochem specializes in the stabilization of carbohydrate molecules to improve their efficacy and safety.
Because carbohydrates have huge potential

- Carbohydrates are involved in numerous biological processes in the body including glycosylation, cell to cell signaling, conferring cell type specificity and helping determine protein structure and function.

- The best examples of carbohydrate-based drugs are the viral neuraminidase inhibitors, Relenza and Tamiflu, which are both used for the treatment of Influenza A.

- Several synthetic heparins are approved as anticoagulants, such as Arixtra and Lovenox.
Why we do it

However…

- Development and commercialization lag due to major drawbacks:
  - Complex synthesis
  - Instability – causing lower efficacy or toxic by products
  - Poor pharmacological properties

Our solution increases the potential and reduces the drawbacks of carbohydrate molecules
How we do it

• Sirona’s Fluorination Chemistry Technology is the solution to unstable carbohydrate molecules.

• We strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule.
How we do it

Carbohydrate molecules are unstable by nature

Our technology stabilizes carbohydrate molecules

Resulting in improved bioavailability and selectivity that translates into better safety and efficacy
How we create revenue

• Sirona’s strategy is to patent and license compounds to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.

• Our SGLT2 inhibitor for diabetes has been licensed to Wanbang/Fosun Pharmaceutical in China and is approved by the CFDA to enter Phase I.

• Our priority in 2019 is to license our skin lightening compound, TFC-1067, to a global industry partner.

• In parallel, we will be advancing our novel anti-wrinkle compound.
Global Skin Lightening Market

<table>
<thead>
<tr>
<th>Year</th>
<th>Asia-Pacific</th>
<th>Japan</th>
<th>ROW (US, Europe)</th>
<th>% CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>7.8</td>
<td>6.8</td>
<td>0.6</td>
<td>9.3</td>
</tr>
<tr>
<td>2015</td>
<td>8.8</td>
<td>7.0</td>
<td>0.6</td>
<td>1.8</td>
</tr>
<tr>
<td>2016</td>
<td>9.9</td>
<td>7.1</td>
<td>0.6</td>
<td>4.2</td>
</tr>
<tr>
<td>2017</td>
<td>11.0</td>
<td>7.3</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>12.1</td>
<td>7.5</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>13.3</td>
<td>7.6</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>14.5</td>
<td>7.7</td>
<td>0.8</td>
<td></td>
</tr>
</tbody>
</table>

Source: Global Industry Analysts

TSX-V: SBM
# Pipeline With Focus On Partnering

## Cosmetic Products

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound</th>
<th>Partnering Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin lightening (Rx &amp; OTC)</td>
<td>TFC-1067 &amp; family of skin lighteners</td>
<td>In partnering discussions</td>
</tr>
<tr>
<td>Cell Preservation &amp; Anti-Wrinkle</td>
<td>Various</td>
<td>In R&amp;D</td>
</tr>
<tr>
<td>Keloid Scar Treatment</td>
<td>Various</td>
<td>In R&amp;D</td>
</tr>
<tr>
<td>Acne/Inflammation</td>
<td>Various</td>
<td>In R&amp;D</td>
</tr>
</tbody>
</table>

## Pharmaceutical Products

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound</th>
<th>Partnering Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>TFC-039</td>
<td>Wanbang / Fosun (China) Ready for licensing in ROW</td>
</tr>
</tbody>
</table>
Locations

Sirona Biochem (Parent Company)
Vancouver, BC, Canada

TFChem (Wholly Owned Subsidiary)
Cosmetic Valley, France

• Sirona Biochem was founded in 2009
• TFChem was acquired in 2011
Investment Highlights

- Sirona Biochem has developed a safe and effective skin lightener (TFC-1067) that is hydroquinone-free with 8 times the efficacy of Deoxyarbutin

- TFC-1067 is currently in clinical trial in the USA

- TFC-039, a diabetes drug, is currently partnered with Wanbang/Fosun (China) and has been approved by the CFDA for clinical trial

- Development of an anti-wrinkle therapy with a novel mechanism of action
Share Capital*

Shares Issued & O/S: 179,825,982
Stock Options: 10,200,000

Warrants - $0.30 strike exp 05/11/2019: 2,073,750
Warrants - $0.25 strike exp 26/10/2019: 4,233,333
Warrants - $0.18 strike exp 16/10/2021: 7,190,420

Shares Issued (Fully Diluted): 203,523,486
Market Cap: $14.38 million

*as of January 2019